Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Virpax Pharmaceuticals
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15
August 08, 2024
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Regains Compliance with Nasdaq Minimum Bid Price
July 24, 2024
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Announces Positive Results of Swine Model Pilot Study for Probudur™
July 10, 2024
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax® Pharmaceuticals to Present at 2024 BIO International Convention
May 29, 2024
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™
April 30, 2024
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing
November 17, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review
October 31, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Gerald W. Bruce Appointed President and CEO of Novvae™ Pharmaceuticals
October 02, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals
September 18, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Pharmaceuticals Updates on Litigation
September 05, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Pharmaceuticals Files Provisional Patent Application for Intranasal Delivery
July 13, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Pharmaceuticals Announces CFO Transition
June 20, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Reports on Progress of Envelta™
April 05, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors
March 28, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET)
February 13, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Pursues OTC Medical Device Pathway for AnQlar™
July 05, 2022
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Will Pursue Direct to OTC Pathway for Epoladerm™ for Pain Associated with Osteoarthritis
June 27, 2022
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax Pharmaceuticals Announces Poster Presentation for Envelta™ at PAINWeek 2021
September 02, 2021
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax® Pharmaceuticals Strengthens Board of Directors with the Appointment of Gerald W. Bruce and Michael F. Dubin, CPA to its Board
July 30, 2021
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Virpax to Use Envelta™ IND Enabling Study Results for Two Additional Indications
June 21, 2021
From
Virpax Pharmaceuticals
Via
Business Wire
Tickers
VRPX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright